Literature DB >> 32073999

Mapping the Molecular Basis and Markers of Papillary Thyroid Carcinoma Progression and Metastasis Using Global Transcriptome and microRNA Profiling.

Ozlem Zeynep Akyay1, Esra Gov2, Halime Kenar3, Kazım Yalcın Arga4, Alev Selek5, İlhan Tarkun6, Zeynep Canturk5, Berrin Cetinarslan5, Yesim Gurbuz7, Busra Sahin7.   

Abstract

Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer (TC). In a subgroup of patients with PTC, the disease progresses to an invasive stage or in some cases to distant organ metastasis. At present, there is an unmet clinical and diagnostic need for early identification of patients with PTC who are at risk of disease progression or metastasis. In this study, we report several molecular leads and potential biomarker candidates of PTC metastasis for further translational research. The study design was based on comparisons of PTC in three different groups using cross-sectional sampling: Group 1, PTC localized to the thyroid (n = 20); Group 2, PTC with extrathyroidal progression (n = 22); and Group 3, PTC with distant organ metastasis (n = 20). Global transcriptome and microRNAs (miRNA) analyses were conducted using an initial screening set comprising nine formalin-fixed paraffin-embedded PTC samples obtained from three independent patients per study group. The findings were subsequently validated by quantitative real-time polymerase chain reaction (qRT-PCR) using the abovementioned independent patient sample set (n = 62). Comparative analyses of differentially expressed miRNAs showed that miR-193-3p, miR-182-5p, and miR-3607-3p were novel miRNAs associated with PTC metastasis. These potential miRNA biomarkers were associated with TC metastasis and miRNA-target gene associations, which may provide important clinicopathological information on metastasis. Our findings provide new molecular leads for further translational biomarker research, which could facilitate the identification of patients at risk of PTC disease progression or metastasis.

Entities:  

Keywords:  biomarkers; genomics; mRNA; metastasis; microRNA; papillary thyroid carcinoma

Mesh:

Substances:

Year:  2020        PMID: 32073999     DOI: 10.1089/omi.2019.0188

Source DB:  PubMed          Journal:  OMICS        ISSN: 1536-2310


  4 in total

1.  Construction of a Signature Model to Predict the Radioactive Iodine Response of Papillary Thyroid Cancer.

Authors:  Lina Liu; Yuhong Shi; Qian Lai; Yuan Huang; Xue Jiang; Qian Liu; Ying Huang; Yuxiao Xia; Dongkun Xu; Zhiqiang Jiang; Wenling Tu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-11       Impact factor: 6.055

Review 2.  Papillary Thyroid Cancer Prognosis: An Evolving Field.

Authors:  Salvatore Ulisse; Enke Baldini; Augusto Lauro; Daniele Pironi; Domenico Tripodi; Eleonora Lori; Iulia Catalina Ferent; Maria Ida Amabile; Antonio Catania; Filippo Maria Di Matteo; Flavio Forte; Alberto Santoro; Piergaspare Palumbo; Vito D'Andrea; Salvatore Sorrenti
Journal:  Cancers (Basel)       Date:  2021-11-07       Impact factor: 6.639

3.  Silencing long non-coding RNA DLX6-AS1 or restoring microRNA-193b-3p enhances thyroid carcinoma cell autophagy and apoptosis via depressing HOXA1.

Authors:  Ling Feng; Ru Wang; Yifan Wang; Xixi Shen; Qian Shi; Meng Lian; Hongzhi Ma; Jugao Fang
Journal:  J Cell Mol Med       Date:  2021-09-12       Impact factor: 5.310

4.  MiR-139 Modulates Cancer Stem Cell Function of Human Breast Cancer through Targeting CXCR4.

Authors:  Chun-Wen Cheng; Wen-Ling Liao; Po-Ming Chen; Jyh-Cherng Yu; Hui-Ping Shiau; Yi-Hsien Hsieh; Huei-Jane Lee; Yu-Chun Cheng; Pei-Ei Wu; Chen-Yang Shen
Journal:  Cancers (Basel)       Date:  2021-05-25       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.